Mylan paid some 75-80% premium to acquire MEDA which could have been 30-40% if markets didn't melt down in past few months.
I m trying to say that current PPS of XNPT may force the street underestimate the upside potential in a BO scenario. This shall go for $8+ in a month or two....
" There is so many good stocks out there with high potential." Can you share a few names? And if the time allows...a little pitch for each of them?
Here's my little pitch for ECYT: stock trading near cash/ 2 drugs in P1 doing good so far/history of partnerships with big pharma Merck/BMS/ credible management / Catalyst: efficacy data at ASCO coming...
In April of 2012, soon after the Merck deal ($120mn upfront), the stock went south for almost a month, everyday. At one time, the stock traded near to $6 (as far i remember) , below it's cash level at that time.
After that we saw highs of $17+ in 2013 and $30+ in 2014.
Market can be irrational at times.
Diamond in the rough ! Exactly.
Can you please share your twitter handle in case you may like to share those analyst reports on request... I would like to follow you.
can you please provide the source of info for what you said:
"There have been unsuccessful attempts to purchase ECYT in the past, prior to going public."
They aren't in mood to partner this as of now. Merck divorce left us with a lot of cash to go forward on our own. That's where the max. value for shareholders come from (and risk too).
and that was obvious.